Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

David R. Matthews; Päivi M. Paldánius; Pieter Proot; YannTong Chiang; Michael Stümvoll; Stefano Del Prato

doi:10.1016/s0140-6736(19)32131-2

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

著者: David R. Matthews, Päivi M. Paldánius, Pieter Proot, YannTong Chiang, Michael Stümvoll, Stefano Del Prato - The Lancet 2019 被引用: 355

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial | Litlas